聚乙二醇干扰素α-2b (Y型,40 kD)注射液治疗基因1/6型慢性丙型肝炎患者的疗效和安全性分析

Bo Feng,Jia Shang,Shuhuan Wu,chenhong,Ying Han,Yueqi Li,Dazhi Zhang,Longfeng Zhao,Shaofeng Wei,Qing Mao,Chibiao Yin,Tao Han,wangmaorong,Shijun Chen,Jun Li,Qing Xie,Zhen Zhen,Zhiliang Gao,Yuexin Zhang,Guozhong Gong,Dongliang Yang,Chen Pan,Jifang Sheng,tanghong,ningqin,Guangfeng Shi,Junqi Niu,Guanghan Luo,Yongtao Sun,youhong,wangguiqiang,Lunli Zhang,Jie Peng,zhangqin,Jiajun Liu,Chengwei Chen,Xinyue Chen,Wei Zhao,wangrunhua,sunli,Lai Wei

聚乙二醇干扰素α-2b (Y型,40 kD)注射液治疗基因1/6型慢性丙型肝炎患者的疗效和安全性分析

2017

目的以标准剂量聚乙二醇干扰素(Peg-IFN) α-2a联合利巴韦林作为阳性对照,评价新型试验药物Peg-IFN α-2b (Y型,40 kD)注射液(180 μg/周)联合利巴韦林治疗1/6型慢性丙型肝炎(CHC)患者的疗效和安全性。方法本研究为多中心、随机开放、阳性药物对照的Ⅲ期临床试验。筛选合格的1/6型CHC患者按照2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations